Articaine hydrochloride + Adrenaline tartrate
Citocartin 200 / Citocartin 100 is used to anesthetize the oral cavity during dental procedures.
This medicine contains two active substances:
Citocartin 200 or Citocartin 100 is administered to the patient by a dentist.
Citocartin 200 / Citocartin 100 is intended for children over 4 years old (approximately 20 kg body weight), adolescents and adults.
Depending on the type of dental procedure, the dentist will decide which of the two medicines to use:
Before starting treatment with Citocartin 200 / Citocartin 100, you should discuss with your dentist if you have any of the following conditions:
You should tell your dentist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
It is especially important to inform your dentist if you are taking any of the following medicines:
You should avoid eating, including chewing gum, until normal sensation returns, due to the risk of biting your lip, cheek, or tongue, especially in children.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your dentist or doctor before using this medicine.
Your dentist or doctor will decide whether you can use Citocartin 200 / Citocartin 100 during pregnancy.
Breastfeeding can be resumed 5 hours after administration of the anesthetic.
No effect on fertility is expected with the doses used during dental procedures.
If you experience side effects, including dizziness, blurred vision, or fatigue, you should not drive or operate machinery until you feel normal again (usually within 30 minutes after the dental procedure).
Only doctors or dentists with proper training should use Citocartin 200 / Citocartin 100.
The dentist will decide whether to use Citocartin 200 or Citocartin 100 and determine the appropriate dose, taking into account the patient's age, body weight, overall health, and dental procedure.
The smallest dose that allows for effective anesthesia should be used.
This medicine is administered by slow injection into the oral cavity.
It is unlikely that the patient will receive too much of this medicine, but if they feel unwell, they should tell their dentist. Symptoms of overdose include severe weakness, paleness, headache, feeling of excitement or overexcitement, feeling of disorientation, loss of balance, involuntary trembling or convulsions, pupil dilation, blurred vision, problems with focusing the eyes on an object, speech disorders, dizziness, convulsions, stupor, loss of consciousness, coma, yawning, abnormally slow or fast breathing, which can lead to temporary cessation of breathing, ineffective heart contractions (called cardiac arrest).
If you have any further doubts about using the medicine, you should consult your dentist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During the patient's stay in the dentist's office, the patient will be closely monitored by the dentist for the effects of Citocartin 200 / Citocartin 100.
Other side effects, not listed above, may also occur in some patients.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your dentist, doctor, or pharmacist.
Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309. Website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored in a place inaccessible to children.
Do not use this medicine after the expiry date stated on the label, blister, and carton after the expiry date (EXP). The expiry date refers to the last day of the month.
Store at a temperature below 25°C.
Cartridges should be stored in the outer packaging to protect from light.
Do not use this medicine if you notice that the solution is cloudy or discolored.
Cartridges are for single use. Use immediately after opening the cartridge.
Any unused solution should be discarded.
Medicines should not be disposed of via wastewater or household waste. Your dentist knows how to dispose of unused medicines. This will help protect the environment.
Each 1.7 ml cartridge of Citocartin 200 solution for injection contains 68 mg of articaine hydrochloride and 0.0085 mg of adrenaline (as adrenaline tartrate).
1 ml of Citocartin 200 contains 40 mg of articaine hydrochloride and 0.005 mg of adrenaline (as adrenaline tartrate).
Each 1.7 ml cartridge of Citocartin 100 solution for injection contains 68 mg of articaine hydrochloride and 0.017 mg of adrenaline (as adrenaline tartrate).
1 ml of Citocartin 100 contains 40 mg of articaine hydrochloride and 0.01 mg of adrenaline (as adrenaline tartrate).
Citocartin 200 / Citocartin 100 is a clear and colorless solution.
It is packaged in single-dose glass cartridges with a rubber stopper at one end and a rubber cap at the other end, placed in aluminum/PVC or paper/PVC blisters in a cardboard box.
Box containing 10 x 1.7 ml glass cartridges.
Box containing 50 x 1.7 ml glass cartridges.
Not all pack sizes may be marketed.
Molteni Dental s.r.l., Via Ilio Barontini 8,
Località Granatieri, 50018 Scandicci (Florence), Italy
Laboratorios Normon S.A.,
Ronda de Valdecarrizo 6,
28760 Tres Cantos, Madrid,
Spain
To obtain more detailed information, you should contact the representative of the marketing authorization holder.
Molteni Stomat Sp. z o.o.,
30-733, Kraków, ul. Obrońców Modlina 3,
Tel. (12) 653 25 85; Fax. (12) 654 15 60
Date of last revision of the leaflet:03/02/2023
Detailed information about this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (http://urpl.gov.pl/pl)
---------------------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
In all populations, the smallest dose should be used that allows for effective anesthesia. The required dose should be determined individually.
For routine procedures in adults, usually 1 cartridge is used, but less than the contents of one cartridge may be sufficient to achieve effective anesthesia. During more extensive procedures, it may be necessary to administer more cartridges, without exceeding the maximum recommended dose; the decision is made by the dentist.
For most routine dental procedures, Citocartin 200 is preferred, (40 mg + 0.005 mg)/ml.
In more complex dental procedures, such as those requiring intensive hemostasis, Citocartin 100 is preferred, (40 mg + 0.01 mg)/ml.
Concomitant use of sedative medications to reduce patient anxiety:
In patients who have been given a sedative, the maximum safe dose of local anesthetic may be reduced due to the additive effect of these medications causing central nervous system depression.
Children and adolescents (12-18 years old)
In adults and adolescents, the maximum dose of articaine is 7 mg/kg body weight, with an absolute maximum dose of articaine of 500 mg. The maximum dose of articaine of 500 mg corresponds to a dose for a healthy adult with a body weight of over 70 kg.
Children (4-11 years old)
The safety of Citocartin in children under 4 years of age has not been established. There are no available data. The amount of medicine to be injected should be determined based on the child's age and body weight, as well as the extent of the procedure. The average effective dose of articaine is 2 mg/kg body weight and 4 mg/kg body weight for simple and complex procedures, respectively. The smallest dose that allows for effective dental anesthesia should be used. In children over 4 years old (or over 20 kg body weight), the maximum dose of articaine is 7 mg/kg body weight, with an absolute maximum dose of 385 mg of articaine for a healthy child with a body weight of 55 kg.
Special patient groups
Elderly patients and patients with kidney disorders:
Due to the lack of clinical data, special precautions should be taken to administer the smallest dose that allows for effective anesthesia in elderly patients and patients with kidney disorders.
In the serum of these patients, increased levels of the product may occur, especially after repeated administration. If it is necessary to repeat the administration of the medicinal product, the patient should be closely monitored to recognize any signs of relative overdose of the product.
Patients with liver function disorders:
Special precautions should be taken to administer the smallest dose that allows for effective anesthesia in patients with liver function disorders, especially after repeated administration, although 90% of articaine undergoes first-pass inactivation by non-specific esterases in tissues and blood.
Patients with cholinesterase deficiency:In patients with cholinesterase deficiency or those being treated with acetylcholinesterase inhibitors, increased levels of the product may occur in the serum, as the product is inactivated by 90% by serum esterases. Therefore, the smallest dose that allows for effective anesthesia should be used.
Infiltration injection and perineural injection in the oral cavity.
Local anesthetics should be injected cautiously in the presence of inflammation and/or infection at the injection site. The rate of injection should be very slow (1 ml/min).
Precautions to be taken before using or administering the medicinal product
This medicinal product should only be used by doctors or dentists with sufficient training and familiarization with the recognition and treatment of systemic toxic effects, or under their supervision. Before inducing local anesthesia with a local anesthetic, you should ensure that appropriate resuscitation equipment and medications are available to allow for immediate treatment of any emergency situations related to the airways and circulation. After each injection of a local anesthetic, the patient's level of consciousness should be monitored.
When using Citocartin for infiltration or conduction anesthesia, the injection should always be performed slowly and with prior aspiration.
Adrenaline disrupts blood flow in the gums, which can lead to local tissue necrosis.
After nerve block anesthesia of the mandible, very rare cases of prolonged or irreversible nerve damage and loss of taste have been reported.
Risks associated with accidental intravascular injection:
Accidental intravascular injection can cause sudden high levels of adrenaline and articaine in the systemic circulation. This can be associated with severe side effects, such as convulsions, followed by central nervous system depression and cardiovascular and respiratory depression, and coma, progressing to respiratory and cardiac arrest.
Therefore, to ensure that the needle does not penetrate a blood vessel during injection, aspiration should be performed before administering the medicinal product. However, the absence of blood in the syringe does not guarantee that the injection will not be administered into a blood vessel.
Risks associated with injection into a nerve:
Accidental injection into a nerve can cause the medicine to be pushed back along the nerve.
To avoid injecting into a nerve and to prevent nerve damage associated with its blockade, the needle should always be gently withdrawn if the patient experiences a sensation similar to an electric shock during insertion or if the insertion is particularly painful. If nerve damage occurs, the neurotoxic effect may be exacerbated due to the potential neurotoxicity of articaine and the presence of adrenaline, as it may impair perineural blood flow and prevent local washing out of articaine.
Before inducing local anesthesia with a local anesthetic, you should ensure that resuscitation equipment and medications are available to allow for immediate treatment of any emergency situations related to the airways and circulation.
The severity of the symptoms of overdose should prompt doctors/dentists to implement protocols that provide for securing the airways and ensuring respiratory support in a timely manner.
After each injection of a local anesthetic, the patient's level of consciousness should be monitored.
In case of acute systemic toxic effects, the injection of the local anesthetic should be stopped immediately. If necessary, the patient's position should be changed to a supine position.
Symptoms from the central nervous system (convulsions, central nervous system depression) should be treated immediately with appropriate airway management and respiratory support, as well as the administration of anticonvulsant medications.
Ensuring optimal oxygen supply and supporting respiration and circulation, as well as treating acidosis, can prevent cardiac arrest.
In case of cardiovascular depression (hypotension, bradycardia), the use of appropriate treatment with intravenous fluids, vasoconstrictors, and/or inotropic agents should be considered. Children should be given doses appropriate for their age and body weight.
In case of cardiac arrest, cardiopulmonary resuscitation should be started immediately.
Do not use this medicinal product if the solution is cloudy or discolored.
To avoid the risk of infection (e.g., transmission of hepatitis), the syringes and needles used to draw up the solution must always be fresh and sterile.
Cartridges are for single use. If only part of the contents has been used, the remainder should be discarded.
Any unused medicinal product or waste material should be disposed of in accordance with local regulations.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.